GMP Securities

GMP Securities L.P.'s predecessor, Griffiths McBurney & Partners, was founded in March 1995 with the vision of creating an energetic, entrepreneurial and independent investment dealer focused on serving corporate clients and institutional investors. Today, GMP Securities is wholly owned by GMP Capital Trust, which converted on December 1, 2005 from GMP Capital Corp. GMP Securities has offered institutional sales, research and trading services to Canadian and U.S. clients since inception and also services European clients through its affiliate GMP Europe. The firm finished sixth in market share on the Toronto Stock Exchange on its first day of operations and year-over-year has the same strong position as a dominant equity block trader. Their affiliates are GMP Private Client L.P. which services high net worth private clients and currently has offices in Toronto, Calgary and Vancouver, and EdgeStone Capital Partners, one of Canada's leading private equity firms with offices in Toronto, Montreal and Calgary.

Nick Bradbrook

Director, Institutional Equity Trading

Christine Drake

CFO and Secretary

Stephen Harris

Vice Chairman and Head of Research

Past deals in Quebec

Troilus Gold

Post in 2020
Troilus Gold is a Canadian based development stage resource company focused on the potential restart and mineral expansion of the former producing Troilus gold and copper mine, located within the Frotêt-Evans Greenstone Belt in Quebec.

Troilus Gold

Post in 2019
Troilus Gold is a Canadian based development stage resource company focused on the potential restart and mineral expansion of the former producing Troilus gold and copper mine, located within the Frotêt-Evans Greenstone Belt in Quebec.

Eastmain Resources

Post in 2018
Eastmain Resources Inc. is a Canadian exploration-stage company focused on acquiring and exploring metallic mineral resource properties, primarily gold, in Ontario and Québec. Established in 1982 and headquartered in Toronto, the company’s flagship project is the Clearwater project in the James Bay region of Québec. Eastmain also holds interests in several other projects, including the Eastmain Mine, Eleonore South Joint Venture, and Lac Lessard, among others. The company emphasizes aggressive exploration for world-class ore deposits and has formed joint ventures and strategic alliances with prominent mining companies to leverage their financial resources and expertise. This approach aims to enhance the company's market share and project advancement in one of the world's most mineral-rich and politically stable regions. As of October 2020, Eastmain operates as a subsidiary of Fury Gold Mines Limited.

Troilus Gold

Post in 2018
Troilus Gold is a Canadian based development stage resource company focused on the potential restart and mineral expansion of the former producing Troilus gold and copper mine, located within the Frotêt-Evans Greenstone Belt in Quebec.

Troilus Gold

Post in 2017
Troilus Gold is a Canadian based development stage resource company focused on the potential restart and mineral expansion of the former producing Troilus gold and copper mine, located within the Frotêt-Evans Greenstone Belt in Quebec.

Integra Resources

Post in 2017
Integra Resources Corp. is a development-stage company based in Vancouver, Canada, focused on the acquisition, exploration, and development of mineral properties primarily in the Americas. The company is centered on its flagship DeLamar project, which includes gold and silver deposits in southwestern Idaho. Additionally, Integra holds an option agreement for the War Eagle Gold-Silver Deposit and has interests in various exploration properties in Ontario and Quebec, Canada. The company is also advancing the Nevada North Project, which encompasses the Wildcat and Mountain View deposits in northwestern Nevada. Furthermore, Integra Resources maintains a portfolio of early-stage exploration projects across Idaho, Nevada, and Arizona.

Knight Therapeutics

Post in 2016
Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Knight Therapeutics

Post in 2016
Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Integra Gold

Post in 2016
Integra Gold is a company that specializes in gold exploration services, focusing on projects and mining operations in Val-d'Or, Québec, a prominent mining region. The company provides a variety of services aimed at facilitating gold exploration, allowing clients to access potential drilling opportunities in this well-regarded jurisdiction. Through its offerings, Integra Gold aims to support the development and advancement of gold mining projects.

Integra Gold

Post in 2016
Integra Gold is a company that specializes in gold exploration services, focusing on projects and mining operations in Val-d'Or, Québec, a prominent mining region. The company provides a variety of services aimed at facilitating gold exploration, allowing clients to access potential drilling opportunities in this well-regarded jurisdiction. Through its offerings, Integra Gold aims to support the development and advancement of gold mining projects.

Integra Gold

Post in 2015
Integra Gold is a company that specializes in gold exploration services, focusing on projects and mining operations in Val-d'Or, Québec, a prominent mining region. The company provides a variety of services aimed at facilitating gold exploration, allowing clients to access potential drilling opportunities in this well-regarded jurisdiction. Through its offerings, Integra Gold aims to support the development and advancement of gold mining projects.

Knight Therapeutics

Post in 2014
Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Knight Therapeutics

Post in 2014
Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.